# Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

> **NCT02393625** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- ALK-positive NSCLC

## Interventions

- **DRUG:** Ceritinib (LDK378)
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02393625
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05-27
- **Primary completion:** 2027-04-09
- **Final completion:** 2027-04-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02393625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02393625, "Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02393625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*